User login
Christopher Flowers, MD, discusses current management strategies for newly diagnosed and relapsed patients with Hodgkin Lymphoma (HL). He also discusses emerging opportunities for the use of novel approaches to treat HL and surveillance of patients with this type of cancer.
"Stem cell transplant still remains the standard approach for patients with relapsed Hodgkin Lymphoma," Flowers said during his presentation during the 2014 AVAHO Meeting's Lymphoma Mini-Symposium. "Turning to the novel agents... there are a number of potential approaches that can be used."
Christopher Flowers, MD, discusses current management strategies for newly diagnosed and relapsed patients with Hodgkin Lymphoma (HL). He also discusses emerging opportunities for the use of novel approaches to treat HL and surveillance of patients with this type of cancer.
"Stem cell transplant still remains the standard approach for patients with relapsed Hodgkin Lymphoma," Flowers said during his presentation during the 2014 AVAHO Meeting's Lymphoma Mini-Symposium. "Turning to the novel agents... there are a number of potential approaches that can be used."
Christopher Flowers, MD, discusses current management strategies for newly diagnosed and relapsed patients with Hodgkin Lymphoma (HL). He also discusses emerging opportunities for the use of novel approaches to treat HL and surveillance of patients with this type of cancer.
"Stem cell transplant still remains the standard approach for patients with relapsed Hodgkin Lymphoma," Flowers said during his presentation during the 2014 AVAHO Meeting's Lymphoma Mini-Symposium. "Turning to the novel agents... there are a number of potential approaches that can be used."
